B+
Bull case
25%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
HROW
HarrowANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$43.50
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$29.00
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-06
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+82.0
Score
AI commentary
Recent news is concentrated around Q2 results and carries a constructive operating tone, but coverage is low. Social sentiment, options skew, short interest, employee sentiment, and post-print analyst revisions are unavailable in the packet; the positive view therefore remains tentative and monitoring-oriented.
RankAlpha Sentiment Codex - 2026-09-06
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-05eventTYRVAYA acquisition closeHigh impact
Harrow announced the acquisition of TYRVAYA, expected to close during the second half of 2026. A successful close could broaden the ophthalmic portfolio, but the value depends on integration, payer access, and commercial execution [#SEC-8K-2026-08-10].
2026-12-05catalystVEVYE access and IHEEZO pricing conversionHigh impact
Expanded VEVYE formulary coverage became effective August 1, while IHEEZO pricing improved approximately 25% effective July 1. The key near-term question is whether these changes convert demand into sustained net revenue and profitability during H2 2026 [#SEC-8K-2026-08-10] [#PR-EARNINGS-2026-08-17].
2026-12-31catalystConversion of H2 demand into 2026 profitabilityHigh impact
Harrow reiterated 2026 revenue guidance of $350 million to $365 million and Adjusted EBITDA guidance of $80 million to $100 million. Sustained VEVYE growth, IHEEZO pricing improvement, and TRIESENCE demand would support the thesis, while failure to convert demand would weaken it [#SEC-8K-2026-08-10].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-06 • Updated nightlySource: Internal modelMethodology